Published in Cancer Weekly, December 4th, 1995
Doxil is indicated for the treatment of Kaposi's sarcoma (KS) in people with AIDS whose KS disease has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Doxil is a Stealth liposome formulation of doxorubicin, an off-patent anticancer drug.
"FDA market clearance of Doxil is a significant milestone for patients with Kaposi's sarcoma," said Chairman and Chief Executive Officer, Dr. I. Craig Henderson. "Doxil is a new...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.